Pharmanutra
Pharmanutra S.p.A., a leading player in the nutraceutical and pharmaceutical sectors, is headquartered in Pisa, Italy, with significant operations across Europe and beyond. Founded in 2003, the company has established itself as a pioneer in the development of innovative iron-based supplements, particularly its flagship product, SiderAL®, which is renowned for its superior bioavailability and effectiveness. With a strong focus on research and development, Pharmanutra has achieved notable milestones, including numerous patents and collaborations with prestigious research institutions. The company’s commitment to quality and scientific validation has positioned it as a trusted name in the industry, catering to both healthcare professionals and consumers. Pharmanutra continues to expand its market presence, driven by a dedication to enhancing health and well-being through its unique range of products.
DitchCarbon Score
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanutra's score of 36 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmanutra's reported carbon emissions
In 2023, Pharmanutra reported total carbon emissions of approximately 1.1 million tonnes CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 229,189 tonnes CO2e, while Scope 2 emissions reached approximately 270,515 tonnes CO2e. Additionally, Scope 3 emissions, which include business travel and employee commuting, accounted for around 684,328 tonnes CO2e and 86,782 tonnes CO2e, respectively. Over the previous years, Pharmanutra's emissions have shown a trend of increase. In 2022, the company recorded about 199,150 tonnes CO2e in Scope 1 and approximately 88,699 tonnes CO2e in Scope 2, alongside Scope 3 emissions of around 69,491 tonnes CO2e from purchased goods and services. The 2021 figures were lower, with Scope 1 emissions at about 137,965 tonnes CO2e and Scope 2 emissions at approximately 66,020 tonnes CO2e. Despite the increasing emissions, Pharmanutra has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company operates within an industry context that increasingly prioritises sustainability and carbon footprint reduction, yet it currently lacks formal commitments to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 61,095 | 00,000 | 00,000 | 000,000 |
| Scope 3 | - | - | 000,000.00 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanutra is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
